Skip to main content
| News

Hemex attracts Swiss investors

11.02.2021

A group of experienced Swiss entrepreneurs and private investors have participated in a significantly oversubscribed financing round for Hemex. The biotech incubator will use the funds to accelerate its global expansion.

Hemex, a Basel Area-based venture capitalist and incubator for biotech startups, has reported raising “a substantial amount” in an oversubscribed Series C financing round. According to a press release, the capital contribution was raised exclusively from a group of Swiss private investors.

Now, Hemex plans to use this money to hire “world-class talent” and accelerate its global expansion. The company wants to “invest in carefully selected startups” and deliver on its promise of “changing the future of healthcare”.

“We anticipate another year of strong growth for healthcare, both domestically and on a global level,” said Hemex CEO Pascal Winnen in the press release. “This vote of confidence for our business model from a group of successful entrepreneurs confirms that Hemex is on the right track for substantial future success.”

Hemex’s partners include the investment and innovation promotion agency Basel Area Business & Innovation and its DayOne Accelerator. Its portfolio includes Opterion Health AG, which announced at the end of January that it would be moving from the canton of Obwalden to the co-working space The 5th Floor in Muttenz. Basel Area Business & Innovation is providing support for the relocation.

In addition, Hemex has invested in Scailyte, a company based at the Novartis Campus of the Switzerland Innovation Park Basel Area. Support has also been provided to Resistell based in Muttenz, which claims to have made the world’s fastest antibiogram, and Basel cancer diagnostics expert Artidis.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Evolva launches new line for manufacturers of personal care products
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech, Sustainability

Evolva launches new line for manufacturers of personal care products

Evolva, a manufacturer of active ingredients based in Reinach in the canton of Basel-Landschaft, will be presenting its new product...

Read More
Record figure for startups in the Basel Area
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Record figure for startups in the Basel Area

Basel Area Business & Innovation has supported a record number of 96 company startups in 2022. The number of settlements...

Read More
Noema Pharma raises 103 million Swiss francs from investors
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Noema Pharma raises 103 million Swiss francs from investors

Noema Pharma has raised a total of 103 million Swiss francs as part of an oversubscribed Series B financing round....

Read More
Why CDMO companies choose the Basel Area as their location
Advanced Manufacturing/AI, Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Why CDMO companies choose the Basel Area as their location

Originally, this article was published by the US magazine Outsourced Pharma under the title "Why Location Matters". The article highlights...

Read More
Basel still the most attractive small city for business in Europe
Basel Area Business & Innovation, Innovation, Invest

Basel still the most attractive small city for business in Europe

As with last year, Basel once again features among the most attractive locations in Europe for investments. It was ranked...

Read More
Ariceum Therapeutics establishes subsidiary in Basel
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Ariceum Therapeutics establishes subsidiary in Basel

The German life sciences firm Ariceum Therapeutics has established a subsidiary in Basel. This company has received support from Basel...

Read More
1 2 3 32

Do you have a question? We'd like to hear from you.